HCG Research: LH/hCG Receptor Pharmacology and Leydig Cell Biology

Human Chorionic Gonadotropin (HCG) is a glycoprotein hormone produced by the syncytiotrophoblast cells of the placenta during pregnancy. It is the signal that maintains the corpus luteum during the first trimester, preventing menstruation and allowing pregnancy to proceed. In laboratory research, HCG is used extensively as a tool compound for studying LHCGR (LH/hCG receptor) pharmacology, Leydig cell steroidogenesis, and gonadal function biology.

Structural Features: Heterodimeric Glycoprotein

HCG is a non-covalent heterodimer consisting of:

Alpha subunit (92 amino acids). The alpha subunit is identical to the alpha subunits of other glycoprotein hormones — luteinizing hormone (LH), follicle-stimulating hormone (FSH), and thyroid-stimulating hormone (TSH). All four hormones share this common alpha subunit, which is not responsible for receptor specificity.

Beta subunit (145 amino acids). The HCG beta subunit is unique and confers LHCGR specificity. It contains a C-terminal extension of approximately 30 amino acids that is absent in the LH beta subunit — the CTP (C-terminal peptide) which carries multiple O-linked sialic acid residues. These sialic acid groups are responsible for HCG's dramatically longer half-life compared to LH.

HCG contains approximately 30% carbohydrate by mass, making glycosylation a major structural feature. The multiple sialylated carbohydrate chains attached to both subunits slow renal clearance and prevent asialoglycoprotein receptor-mediated hepatic uptake, extending the plasma half-life to 24-36 hours versus 20-30 minutes for LH.

LHCGR Pharmacology

The LH/hCG receptor (LHCGR) is a Gs-coupled class A GPCR that activates cAMP/PKA signalling in target cells. It is expressed predominantly on:

• Leydig cells (testis): testosterone production
• Theca cells (ovary): androgen production for oestrogen synthesis
• Corpus luteum: progesterone maintenance
• Granulosa cells (post-LH surge): ovulation signalling

Both LH and HCG activate LHCGR with similar potency, but their dramatically different half-lives produce very different pharmacodynamic profiles. LH produces acute pulsatile LHCGR stimulation that drives the testosterone pulses and ovulatory LH surge. HCG produces sustained LHCGR stimulation — which is both its physiological role (maintaining corpus luteum) and its research utility (enabling chronic Leydig cell stimulation without repeated dosing).

Leydig Cell Steroidogenesis Research

The Leydig cell steroidogenesis pathway from cholesterol to testosterone is one of the most studied endocrine signalling cascades. HCG is the standard LHCGR agonist for studying this pathway:

1. HCG binds LHCGR → Gs activation → adenylyl cyclase → cAMP elevation
2. PKA activation → StAR protein phosphorylation and upregulation
3. StAR transports cholesterol across the inner mitochondrial membrane
4. CYP11A1 (cholesterol side-chain cleavage enzyme) converts cholesterol to pregnenolone
5. CYP17A1 (17-hydroxylase/17,20-lyase) converts pregnenolone to DHEA
6. HSD17B3 converts androstenedione to testosterone

HPG Axis Research Position

In the HPG axis research hierarchy, HCG occupies the gonadal level — downstream of pituitary LH secretion (which is driven by GnRH from the hypothalamus, measured using Gonadorelin research tools, and modulated by KNDy neurons examined with Kisspeptin-10). Using HCG alongside Gonadorelin and Kisspeptin-10 allows comprehensive study of the complete HPG axis from hypothalamic KNDy neurons through pituitary gonadotrophs to gonadal steroidogenesis.

Published Research References

LHCGR Signal Transduction in Detail

The LH/hCG receptor (LHCGR) signal transduction cascade is one of the most thoroughly characterised steroidogenic signalling pathways in endocrinology. Following HCG binding, the complete cascade from receptor activation to testosterone production involves:

Gs/cAMP pathway. HCG-LHCGR interaction activates Gs, stimulating adenylyl cyclase to produce cAMP. cAMP activates PKA by dissociating its regulatory subunits, freeing catalytic subunits that translocate to the nucleus and mitochondria. PKA phosphorylates and activates multiple steroidogenic pathway components simultaneously.

StAR protein. The steroidogenic acute regulatory protein (StAR) is the rate-limiting acute regulator of steroidogenesis. PKA phosphorylates StAR at Ser194, activating its cholesterol transport function — physically shuttling cholesterol from outer to inner mitochondrial membrane. StAR expression is also transcriptionally upregulated by PKA via CREB. StAR-null mice and humans with StAR mutations have lipoid congenital adrenal hyperplasia (no steroid production), establishing StAR as the essential cholesterol transporter.

CYP11A1 (P450scc). Cholesterol side-chain cleavage enzyme resides on the inner mitochondrial membrane matrix side and converts cholesterol to pregnenolone — the committed first step of steroidogenesis. This enzyme requires cholesterol delivery via StAR and electrons from adrenodoxin reductase/adrenodoxin.

Downstream steroidogenic enzymes. CYP17A1 (17-hydroxylase/17,20-lyase) converts pregnenolone to DHEA via 17-hydroxypregnenolone; HSD3B converts DHEA to androstenedione; HSD17B3 converts androstenedione to testosterone. Each step is a potential research target when using HCG as the upstream LHCGR stimulus.

HCG versus LH as Research Tools

While functionally equivalent as LHCGR agonists, HCG and LH have practical research differences beyond half-life:

Receptor binding kinetics. HCG binds LHCGR with slightly higher affinity than LH (approximately 2-3 fold lower Kd) due to the C-terminal peptide (CTP) of the HCG beta subunit interacting with the leucine-rich repeat domain of LHCGR's extracellular domain. This higher affinity means HCG requires lower molar concentrations to achieve equivalent receptor occupancy.

Receptor internalisation. HCG produces more prolonged LHCGR activation and slower receptor internalisation than LH, reflecting its higher affinity and longer receptor residency time. For studies examining LHCGR trafficking and desensitisation kinetics, this distinction is research-relevant.

Availability and purity. HCG as a research compound is typically derived from pregnancy urine or produced recombinantly, with potency measured in international units (IU) rather than by mass — reflecting its glycoprotein nature and the importance of biological activity rather than molecular weight for functional assays.

Fertility Research Applications

HCG's role in reproductive biology extends beyond simple LHCGR activation. Research applications in fertility biology include:

Corpus luteum maintenance. HCG is the signal that prevents corpus luteum regression during early pregnancy. Research models examining luteal cell steroidogenesis, progesterone production, and corpus luteum lifespan use HCG as the stimulus to maintain luteal function in vitro beyond the normal 14-day luteal phase duration.

Follicular maturation. In ovarian granulosa cell research, HCG (or LH) triggers the final maturation steps including cumulus expansion, oocyte maturation resumption (germinal vesicle breakdown), and prostaglandin-mediated follicle rupture. These processes are studied in HCG-stimulated granulosa cell culture systems.

Leydig cell development. During fetal testicular development, HCG from the placenta drives Leydig cell differentiation and testosterone production in the masculinisation window. Research using HCG in primary fetal or neonatal Leydig cell cultures examines the developmental steroidogenesis programme.

Published Research References

For laboratory and analytical research purposes only. Not for human or veterinary use.

Related research peptides: Gonadorelin Acetate | Kisspeptin-10
View HCG product and buy →

Glycoprotein Hormone Family: Structural Relationships

HCG belongs to the cystine-knot glycoprotein hormone superfamily alongside LH, FSH, and TSH. All four hormones share the same alpha subunit (the "common alpha" or CGA gene product, 92 amino acids) and have unique beta subunits that determine receptor specificity. The alpha subunit contains two N-linked glycosylation sites (Asn52 and Asn78), and all four hormones' alpha subunits are identical — a remarkable evolutionary conservation.

The receptor specificity resides entirely in the beta subunit. The HCG beta subunit (145 amino acids) shares approximately 82% sequence identity with the LH beta subunit (121 amino acids) — their primary difference is the C-terminal extension (CTP) in the HCG beta subunit containing four O-linked sialylated sugar chains that are absent from the LH beta subunit. These sialic acid residues extend the HCG half-life from LH's 20-30 minutes to HCG's 24-36 hours, enabling HCG to maintain corpus luteum function throughout the first trimester of pregnancy without continuous pituitary LH secretion.

LHCGR Internalisation and Spare Receptor Concept

LHCGR, like most GPCRs, exhibits receptor internalisation following sustained agonist binding. However, Leydig cells display a phenomenon called "spare receptors" — at maximal testosterone production (Vmax), only approximately 1% of total LHCGR need to be occupied. This spare receptor pool means that modest reductions in LHCGR surface density (through partial internalisation) do not immediately reduce steroidogenic output.

Research implications: HCG desensitisation studies in Leydig cells must account for this spare receptor phenomenon. The concentration of HCG needed to half-maximally stimulate testosterone production (EC50) does not reflect the concentration needed for half-maximal receptor occupancy (Kd). The 1% spare receptor reserve means that testosterone production can be maintained at near-maximal rates even when 99% of receptors are occupied — a situation where further LHCGR stimulation would appear to produce no additional effect despite incomplete receptor occupancy.

Frequently Asked Questions

What is the difference between HCG for research and urinary HCG used in pregnancy tests?
Pregnancy tests detect urinary HCG, which is produced by placental syncytiotrophoblasts and excreted in urine. Research-grade HCG is purified from pregnancy urine or produced recombinantly, then characterised for biological activity (IU/mg) and molecular identity. Signal Labs research HCG is supplied in IU (international units) rather than mass, reflecting the activity-based characterisation appropriate for glycoprotein hormones. The IU is defined by reference to WHO international standards for HCG potency, enabling consistent biological activity specification across different preparations and manufacturers.

How should HCG research experiments be controlled?
Standard controls for HCG Leydig cell research include: vehicle control (reconstitution buffer alone at equivalent volume), LH-positive control at maximal steroidogenic concentration to establish Vmax, and LHCGR-antagonist-treated wells (using a competitive LHCGR antagonist or LHCGR-neutralising antibody) to confirm that observed effects are receptor-mediated. Time-course experiments should include HCG removal conditions (wash-out protocol) to characterise whether steroidogenic effects persist after agonist removal — relevant for comparing HCG's sustained LHCGR activation with LH's more transient stimulation.

Browse all Signal Labs research peptides | Peptide storage guide | Reconstitution guide